RU2018145945A - Пептид для лечения остеоартрита, фармацевтическая композиция, лекарственное средство, единичная дозированная форма - Google Patents
Пептид для лечения остеоартрита, фармацевтическая композиция, лекарственное средство, единичная дозированная форма Download PDFInfo
- Publication number
- RU2018145945A RU2018145945A RU2018145945A RU2018145945A RU2018145945A RU 2018145945 A RU2018145945 A RU 2018145945A RU 2018145945 A RU2018145945 A RU 2018145945A RU 2018145945 A RU2018145945 A RU 2018145945A RU 2018145945 A RU2018145945 A RU 2018145945A
- Authority
- RU
- Russia
- Prior art keywords
- lys
- ser
- asp
- seq
- thr
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 13
- 239000002552 dosage form Substances 0.000 title claims 5
- 239000003814 drug Substances 0.000 title claims 4
- 239000008194 pharmaceutical composition Substances 0.000 title claims 4
- 229940079593 drug Drugs 0.000 title claims 3
- 201000008482 osteoarthritis Diseases 0.000 title claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 4
- 235000004279 alanine Nutrition 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- 235000008729 phenylalanine Nutrition 0.000 claims 2
- 210000001179 synovial fluid Anatomy 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- 235000002374 tyrosine Nutrition 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- BBBXWRGITSUJPB-YUMQZZPRSA-N Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O BBBXWRGITSUJPB-YUMQZZPRSA-N 0.000 claims 1
- UQHGAYSULGRWRG-WHFBIAKZSA-N Glu-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CO)C(O)=O UQHGAYSULGRWRG-WHFBIAKZSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- CIOWSLJGLSUOME-BQBZGAKWSA-N Lys-Asp Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O CIOWSLJGLSUOME-BQBZGAKWSA-N 0.000 claims 1
- IWWMPCPLFXFBAF-SRVKXCTJSA-N Lys-Asp-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O IWWMPCPLFXFBAF-SRVKXCTJSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- LTFSLKWFMWZEBD-IMJSIDKUSA-N Ser-Asn Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O LTFSLKWFMWZEBD-IMJSIDKUSA-N 0.000 claims 1
- VBKBDLMWICBSCY-IMJSIDKUSA-N Ser-Asp Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O VBKBDLMWICBSCY-IMJSIDKUSA-N 0.000 claims 1
- DZHDVYLBNKMLMB-ZFWWWQNUSA-N Trp-Lys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 DZHDVYLBNKMLMB-ZFWWWQNUSA-N 0.000 claims 1
- WKQNLTQSCYXKQK-VFAJRCTISA-N Trp-Lys-Thr Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WKQNLTQSCYXKQK-VFAJRCTISA-N 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- ZVDPYSVOZFINEE-BQBZGAKWSA-N alpha-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O ZVDPYSVOZFINEE-BQBZGAKWSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 108010003700 lysyl aspartic acid Proteins 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16174056 | 2016-06-10 | ||
| EP16174056.8 | 2016-06-10 | ||
| PCT/EP2017/064196 WO2017212057A1 (en) | 2016-06-10 | 2017-06-09 | Peptides for the treatment of osteoarthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018145945A3 RU2018145945A3 (enExample) | 2020-07-10 |
| RU2018145945A true RU2018145945A (ru) | 2020-07-10 |
Family
ID=56132793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018145945A RU2018145945A (ru) | 2016-06-10 | 2017-06-09 | Пептид для лечения остеоартрита, фармацевтическая композиция, лекарственное средство, единичная дозированная форма |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10813980B2 (enExample) |
| EP (1) | EP3468582A1 (enExample) |
| JP (1) | JP7010934B2 (enExample) |
| KR (1) | KR20190018466A (enExample) |
| CN (1) | CN109862905A (enExample) |
| AU (1) | AU2017277747A1 (enExample) |
| BR (1) | BR112018075613A2 (enExample) |
| CA (1) | CA3026984A1 (enExample) |
| IL (1) | IL263564B (enExample) |
| MA (1) | MA45227A (enExample) |
| RU (1) | RU2018145945A (enExample) |
| WO (1) | WO2017212057A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108785661A (zh) * | 2018-07-20 | 2018-11-13 | 深圳市第二人民医院 | 一种无副作用治疗退行性骨关节病的注射剂及其制备方法 |
| IL280880B2 (en) | 2018-08-27 | 2025-04-01 | Regeneron Pharma | Using Raman Spectroscopy in Downstream Purification |
| KR102856432B1 (ko) | 2022-02-23 | 2025-09-08 | 중앙대학교 산학협력단 | 졸참나무 잎 추출물을 유효성분으로 포함하는 골관절염 예방 또는 치료용 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1208760B (it) * | 1986-11-04 | 1989-07-10 | Ind Farmaceutica Serono S P A | Trattamento delle malattie infiammatorie articolari |
| FR2833012B1 (fr) * | 2001-12-04 | 2004-01-30 | Centre Nat Rech Scient | Peptides agonistes de l'hormone de croissance et leurs applications |
| US20040127402A1 (en) * | 2002-12-27 | 2004-07-01 | Vad Vijay B. | Injectible composition and method for treating degenerative animal joints |
| US7803781B2 (en) * | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
| US20070184015A1 (en) | 2006-02-03 | 2007-08-09 | Soonkap Hahn | Novel PEGylation agent |
| CA2755436C (en) * | 2009-03-19 | 2019-10-29 | Claude Carelli | Peptides for inhibiting igf-1 |
| ES2616004T3 (es) * | 2009-11-18 | 2017-06-09 | Asahi Kasei Pharma Corporation | Agente profiláctico y/o agente terapéutico y/o agente supresor de exacerbación para osteortritis de rodilla humana |
-
2017
- 2017-06-09 US US16/308,520 patent/US10813980B2/en not_active Expired - Fee Related
- 2017-06-09 BR BR112018075613-0A patent/BR112018075613A2/pt not_active IP Right Cessation
- 2017-06-09 EP EP17730751.9A patent/EP3468582A1/en not_active Withdrawn
- 2017-06-09 JP JP2019517165A patent/JP7010934B2/ja not_active Expired - Fee Related
- 2017-06-09 WO PCT/EP2017/064196 patent/WO2017212057A1/en not_active Ceased
- 2017-06-09 AU AU2017277747A patent/AU2017277747A1/en not_active Abandoned
- 2017-06-09 CN CN201780042664.6A patent/CN109862905A/zh active Pending
- 2017-06-09 KR KR1020197000187A patent/KR20190018466A/ko not_active Ceased
- 2017-06-09 RU RU2018145945A patent/RU2018145945A/ru not_active Application Discontinuation
- 2017-06-09 CA CA3026984A patent/CA3026984A1/en not_active Abandoned
- 2017-06-09 MA MA045227A patent/MA45227A/fr unknown
-
2018
- 2018-12-06 IL IL263564A patent/IL263564B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018145945A3 (enExample) | 2020-07-10 |
| BR112018075613A2 (pt) | 2019-04-09 |
| IL263564B (en) | 2021-07-29 |
| CN109862905A (zh) | 2019-06-07 |
| WO2017212057A1 (en) | 2017-12-14 |
| MA45227A (fr) | 2019-04-17 |
| JP7010934B2 (ja) | 2022-02-10 |
| US10813980B2 (en) | 2020-10-27 |
| IL263564A (en) | 2019-02-03 |
| KR20190018466A (ko) | 2019-02-22 |
| AU2017277747A1 (en) | 2019-01-17 |
| CA3026984A1 (en) | 2017-12-14 |
| US20190298808A1 (en) | 2019-10-03 |
| EP3468582A1 (en) | 2019-04-17 |
| JP2019522046A (ja) | 2019-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018504901A5 (enExample) | ||
| RU2012140704A (ru) | Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция | |
| MX2020004969A (es) | Composiciones y procedimientos para tratar cancer. | |
| RU2019126232A (ru) | Пептиды и способы для лечения диабета | |
| JP7580404B2 (ja) | Ｇｌｐ１／２二重アゴニストの非経口医薬組成物 | |
| RU2015147876A (ru) | Пероральная дозированная форма соединений глюкагоноподобного пептида-1 | |
| JP2019533722A5 (enExample) | ||
| JP2011523935A5 (enExample) | ||
| CN106604915A (zh) | 关节病症的治疗 | |
| RU2018145945A (ru) | Пептид для лечения остеоартрита, фармацевтическая композиция, лекарственное средство, единичная дозированная форма | |
| AR068020A1 (es) | Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico | |
| JP2025121987A (ja) | Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物 | |
| EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
| WO2022177878A1 (en) | Glucagon-like peptide-1 receptor antagonists | |
| JP2019522046A5 (enExample) | ||
| AU2021404497A1 (en) | Pharmaceutical composition of glp-1/glp-2 dual agonists | |
| EP4262746A1 (en) | Pharmaceutical composition of glp-1/glp-2 dual agonists | |
| JP2008543961A5 (enExample) | ||
| EA202092366A1 (ru) | Применение происходящих из pedf коротких пептидов при лечении остеоартрита | |
| RU2012100241A (ru) | Лечение хориоидальной неоваскуляризации с помощью вакцин | |
| RU2007115411A (ru) | Пептиды hsp60 и их apl-производные и фармацевтические композиции | |
| EP3212219A1 (en) | New indication for alpha-msh analogues | |
| RU2019135294A (ru) | Полипептид, композиция, фармацевтическая композиция, лекарственное средство, диетическая добавка, пищевая композиция, применения полипептида, фармацевтической композиции, лекарственного средства, диетической добавки, пищевой композиции для лечения ожирения и снижения веса | |
| RU2016112931A (ru) | Композиции новых пептидов | |
| WO2015063102A1 (en) | Alpha-msh analogues for use in bullous disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20201019 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20210803 |
|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20220117 |